IRIS
LODOLA, Alessio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.174
NA - Nord America 3.926
AS - Asia 1.718
AF - Africa 73
Continente sconosciuto - Info sul continente non disponibili 5
SA - Sud America 3
Totale 9.899
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.875
IT - Italia 1.106
CN - Cina 1.103
IE - Irlanda 821
FI - Finlandia 702
SE - Svezia 636
DE - Germania 346
SG - Singapore 273
UA - Ucraina 228
TR - Turchia 175
FR - Francia 89
IN - India 88
CI - Costa d'Avorio 69
AT - Austria 56
GB - Regno Unito 54
CA - Canada 51
BE - Belgio 48
VN - Vietnam 34
CZ - Repubblica Ceca 29
HK - Hong Kong 21
NL - Olanda 14
ES - Italia 13
JP - Giappone 9
RO - Romania 7
PL - Polonia 6
HR - Croazia 5
PK - Pakistan 5
EU - Europa 4
HU - Ungheria 4
AR - Argentina 3
NO - Norvegia 3
TH - Thailandia 3
TW - Taiwan 3
CH - Svizzera 2
EG - Egitto 2
IR - Iran 2
RU - Federazione Russa 2
A1 - Anonimo 1
BG - Bulgaria 1
JO - Giordania 1
LU - Lussemburgo 1
MC - Monaco 1
MY - Malesia 1
NG - Nigeria 1
SC - Seychelles 1
Totale 9.899
Salva come PNG Salva come JPEG
Città #
Dublin 814
Chandler 742
Parma 426
Ann Arbor 398
Jacksonville 293
Ashburn 251
Dearborn 246
Beijing 240
Boardman 221
Singapore 192
Nanjing 163
Izmir 160
Shanghai 145
Princeton 136
Wilmington 112
New York 107
Bremen 79
San Mateo 77
Helsinki 76
Abidjan 69
Shenyang 67
Milan 54
Vienna 50
Jinan 46
Kunming 45
Hebei 44
Los Angeles 43
Nanchang 42
Brussels 41
Hefei 38
Toronto 38
Des Moines 37
Seattle 37
Bologna 35
Düsseldorf 35
Dong Ket 34
Santa Clara 34
Jiaxing 32
Modena 32
Guangzhou 31
Munich 31
Woodbridge 30
Changsha 29
Bangalore 27
Fremont 27
Brescia 20
Brno 20
Dallas 20
Pune 20
Tianjin 19
Norwalk 18
Hangzhou 17
Zhengzhou 16
Ankara 14
Grafing 14
Hong Kong 14
Rome 13
London 12
Prata Di Pordenone 12
Houston 11
Palermo 11
Verona 11
Auburn Hills 9
Borås 9
Fairfield 9
Marseille 9
Weihai 8
Falls Church 7
Fuzhou 7
Hyderabad 7
Lubbock 7
Neviano degli Arduini 7
Ningbo 7
Piacenza 7
Redmond 7
Soliera 7
Taizhou 7
Washington 7
Ardea 6
Caorso 6
Follonica 6
Haikou 6
Ottawa 6
Redwood City 6
Rimini 6
Sant'ilario D'enza 6
Tokyo 6
Vigevano 6
Canneto sull'Oglio 5
Casalgrande 5
Chengdu 5
Delhi 5
Genoa 5
Leuven 5
Madrid 5
Montegaldella 5
Montreal 5
Naples 5
Paris 5
Pavia 5
Totale 6.409
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 206
Targeting the Eph/ephrin system as anti-inflammatory strategy in IBD 159
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 154
Benzisothiazolinone Derivatives as Potent Allosteric Monoacylglycerol Lipase Inhibitors That Functionally Mimic Sulfenylation of Regulatory Cysteines 137
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 134
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 127
inibitori eph-ephrin biodisponibili oralmente 122
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 119
Dibasic biphenyl H(3) receptor antagonists: Steric tolerance for a lipophilic side chain. 108
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 108
Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation 107
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 106
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 105
Amino acid derivatives as palmitoylethanolamide prodrugs: Synthesis, in vitro metabolism and in vivo plasma profile in rats 103
Application of 3D-QSAR in the Rational Design of Receptor Ligands and Enzyme Inhibitors 102
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 101
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 101
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph–Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice 100
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 93
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 93
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 92
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 92
N-Acylethanolamine Acid Amidase (NAAA): Structure, Function, and Inhibition 91
Biphenyl-3-yl alkylcarbamates as fatty acid amide hydrolase (FAAH) inhibitors: steric effects of N-alkyl chain on rat plasma and liver stability 90
Application of a SCC-DFTB QM/MM approach to the investigation of the catalytic mechanism of fatty acid amide hydrolase. 90
Discovery and development of small molecules targeting Eph-ephrin system in glioblastoma: an academic history 88
The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells 88
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 88
Free-Energy Simulations Support a Lipophilic Binding Route for Melatonin Receptors 85
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 83
A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors. 83
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 83
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 83
Eph-ephrin antagonism in tumor angiogenesis and growth: UniPR1331 preclinical evidence. 80
Cyclohexylcarbamic Acid 3'- or 4'-Substituted Biphenyl-3-yl Esters of as Fatty Acid Amide Hydrolase Inhibitors: Synthesis, Quantitative Structure-Activity Relationships and Molecular Modelling Studies 79
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 79
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 78
A catalytic mechanism for cysteine N-terminal nucleophile hydrolases, as revealed by free energy simulations 77
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 77
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 77
UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice 77
Eph/ephrin targeting with a small molecule improves glucose tolerance in healthy and insulin-resistant mice 76
QM/MM modelling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation 76
A sulfonyl fluoride derivative inhibits EGFR L858R/T790M/C797S by covalent modification of the catalytic lysine 76
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 75
Pushing the Boundaries of Vinylogous Reactivity: Catalytic Enantioselective Mukaiyama Aldol Reactions of Highly Unsaturated 2-Silyloxyindoles 75
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 74
N-(2-Oxo-3-oxetanyl)carbamic Acid Esters as N-Acylethanolamine Acid Amidase Inhibitors: Synthesis, Structure–Activity and Structure–Property Relationships. 73
Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists 72
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 72
N-Acylethanolamine Acid Amidase (NAAA): Mechanism of Palmitoylethanolamide Hydrolysis Revealed by Mechanistic Simulations 72
UniPR1331: small Eph/ephrin antagonist beneficial in intestinal inflammation by interfering with type-B signaling 72
Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids 72
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 71
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 70
Aromatic interactions and rotational strengths within protein environment: An electronic structural study on beta-lactamases from class A 70
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 70
Predicting the reactivity of nitrile-carrying compounds with cysteine: a combined computational and experimental study. 70
Synthesis, Pharmacological Evaluation and Structure-Activity Relationships of Benzopyran Derivatives with Potent SERM Activity 69
MT2 selective melatonin receptor antagonists: design and structure-activity relationships 69
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 69
Tetrahydroquinoline Ring as a Versatile Bioisostere of Tetralin for Melatonin Receptor Ligands 69
Evaluation of the anti-tumor activity of small molecules targeting eph/ephrins in apcmin j mice 69
Applications and Advances of QM/MM methods in Computational Enzymology 68
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 68
Irreversible EGFR inhibitor compounds with antiproliferative activity 68
Atropisomerism and Conformational Equilibria: Impact on PI3Kδ Inhibition of 2-((6-Amino-9H-purin-9-yl)methyl)-5-methyl-3-(o-tolyl)quinazolin-4(3H)-one (IC87114) and Its Conformationally Restricted Analogs 68
L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib 68
PHARMACOLOGICAL CHARACTERIZATION OF NEW COMPOUNDS AIMED AT INHIBITING EPH-EPHRIN INTERACTION IN GLIOBLASTOMA 67
NEW EPH ANTAGONISTS DISCRIMINATING BETWEEN EPH-AS AND EPH-BS CLASSES 67
Catalytic, Asymmetric Hypervinylogous Mukaiyama Aldol Reactions of Extended Furan-Based Silyl Enolates 67
Structure activity relationship of new EphA2 ligands 67
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 67
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 66
N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe (BOC2) inhibits the angiogenic activity of heparin-binding growth factors. 65
Mechanistic Insights into the Reaction of Chlorination of Tryptophan Catalyzed by Tryptophan 7-Halogenase 65
Lithocholic acid competitively inhibits EphA2-ephrinA1 binding: pharmacological and structural considerations. 64
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 64
On the Use of 2,5-Dimethyl-Pyrrol-1-yl-Benzoic Acid Derivatives as EPH-Ephrin Antagonists. 64
Metadynamics Simulations Distinguish Short- and Long-Residence-Time Inhibitors of Cyclin-Dependent Kinase 8. 64
Lithocholic acid competitively inhibitis EphA2-ephrinA1 binding: pharmacological and structural considerations. 63
Therapeutic perspectives of Eph–ephrin system modulation 63
Lithocholic Acid Is an Eph-ephrin Ligand Interfering with Eph-kinase Activation. 63
Identification of bivalent ligands with melatonin receptor agonist and fatty acid amide hydrolase (FAAH) inhibitory activity that exhibit ocular hypotensive effect in the rabbit 63
Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands. 62
APPLICATION OF COMPUTATIONAL METHODSTO THE DESIGN OF FATTY ACID AMIDE HYDROLASE(FAAH) INHIBITORS BASED ON A CARBAMICTEMPLATE STRUCTURE 61
Synthesis, Enantiomeric Resolution, and Structure-Activity Relationship Study of a Series of 10,11-Dihydro-5H-Dibenzo[a,d]cycloheptene MT(2) Receptor Antagonists. 60
Optimizing EGFR inhibitor treatment in non small cell lung cancer 57
Quantum mechanics/molecular mechanics modeling of covalent addition between EGFR-cysteine 797 and N -(4-Anilinoquinazolin-6-yl) acrylamide 57
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 57
Mechanistic Modeling of Lys745 Sulfonylation in EGFR C797S Reveals Chemical Determinants for Inhibitor Activity and Discriminates Reversible from Irreversible Agents 57
Understanding the role of carbamate reactivity in fatty acid amide hydrolase inhibition by QM/MM mechanistic modelling. 56
Are we using the right pharmacological tools to target EphA4? 56
Design and SAR Analysis of Covalent Inhibitors Driven by Hybrid QM/MM Simulations 56
N-(Substituted-anilinoethyl)amides: Design, Synthesis and Pharmacological Characterization of a New Class of Melatonin Receptor Ligands. 56
Quantitative structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors. 56
Analysis of adam12-mediated ephrin-a1 cleavage and its biological functions 55
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors 55
In vitro and in vivo efficacy of an orally bioavailable antagonist of Eph-ephrin system in tumor angiogenesis and growth 55
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 53
Totale 8.014
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.621
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.621
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.104 0 0 0 32 121 207 226 47 185 140 64 82
2020/20211.022 22 79 88 77 125 59 124 43 194 41 88 82
2021/2022850 30 24 24 86 58 28 109 100 58 67 35 231
2022/20233.112 314 309 172 240 288 358 41 196 983 45 127 39
2023/20241.256 82 72 42 43 89 270 118 111 46 64 142 177
2024/2025654 137 217 271 29 0 0 0 0 0 0 0 0
Totale 10.195